NCT04298879 is a Phase 2 clinical trial of IBI376 in Indolent Non-hodgkin Lymphoma, sponsored by Innovent Biologics (Suzhou) Co. Ltd..

Who is sponsoring NCT04298879?

NCT04298879 is sponsored by Innovent Biologics (Suzhou) Co. Ltd..

What drugs are being tested in NCT04298879?

Interventions in NCT04298879: IBI376.

What condition does NCT04298879 study?

NCT04298879 studies Indolent Non-hodgkin Lymphoma.

Is NCT04298879 still recruiting?

NCT04298879 is currently completed. Last updated 5 June 2024.

Last reviewed 2024-06-05 · How we verify

NCT04298879

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IBI376 in Patients With Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Completed Phase 2 Last updated 5 June 2024

What this trial tests

Phase 2 trial testing IBI376 in Indolent Non-hodgkin Lymphoma in 81 participants. Completed in 21 November 2023.

Timeline

7 April 2020

Primary endpoint
27 July 2021

21 November 2023

Quick facts

Lead sponsor	Innovent Biologics (Suzhou) Co. Ltd.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	81
Start date	7 April 2020
Primary completion	27 July 2021
Estimated completion	21 November 2023
Sites	1 location across China

Drugs / interventions tested

IBI376 — full drug profile →

Conditions studied

Indolent Non-hodgkin Lymphoma — all drugs for Indolent Non-hodgkin Lymphoma →

Sponsor

Innovent Biologics (Suzhou) Co. Ltd. — full company profile →

Who can join

18 and older, any sex, with Indolent Non-hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 2, Multicenter, Open-Label Study of IBI376, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers.
Shan KS, Bonano-Rios A, Theik NWY, Hussein A, et al · · 2024 · cited 19× · PMID 38396649 · DOI 10.3390/ijms25041973
Tumor-infiltrating regulatory T cell: A promising therapeutic target in tumor microenvironment.
Huang T, Li F, Wang Y, Gu J, et al · · 2024 · cited 2× · PMID 39679474 · DOI 10.1097/cm9.0000000000003450
P1099: A PHASE II, MULTICENTER, SINGLE-ARM STUDY OF PARSACLISIB, A PI3KΔ INHIBITOR, IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA IN CHINA: UPDATED RESULTS FROM THE STUDY
Zheng Z, Zhang H, Zhou K, Zhou H, et al · · 2023

Verify or expand the search:

Other trials of IBI376

Trials testing the same drug.

NCT05073250 — IBI376 Plus Rituximab in Patients With Untreated Indolent Lymphoma. · Phase 2 · unknown

Other recruiting trials for Indolent Non-hodgkin Lymphoma

Currently open trials in the same condition.

NCT04223765 — Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refracto · Phase 1 · recruiting
NCT03198026 — Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · Phase 2 · active not recruiting

Other Innovent Biologics (Suzhou) Co. Ltd. trials

Trials by the same sponsor.

NCT07502534 — A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers · Phase 1 · not yet recruiting
NCT07469800 — Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity · Phase 3 · not yet recruiting
NCT07473960 — IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia · Phase 3 · recruiting
NCT07483567 — IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastri · Phase 2 · not yet recruiting
NCT07483554 — IBI343 in Combination Therapy for Advanced Malignant Solid Tumors · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04298879 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Innovent Biologics (Suzhou) Co. Ltd.
Last refreshed: 5 June 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04298879.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing